Supersize my Pipeline
Edyta Zielinska | Apr 1, 2009
Will Exelixis's novel approach pay off in the current economic climate?
Personalized Meddling
Andrea Gawrylewski | Mar 1, 2009
Frankie Trull wants to sell your company to Congress.
Profiting from Pluripotency
Elie Dolgin | Feb 1, 2009
How companies plan to make money (really) off of embryonic stem cells.
The Mentorship Market
Bob Grant | Jan 1, 2009
New organizations want to help you succeed in biotech - for free.
Morale Mire
Fran Hawthorne | Dec 1, 2008
FDA scientists are increasingly unhappy, due to in-house pressures and public criticism. How can the agency restore what it once was?
Serotonin, Repurposed
Andrea Gawrylewski | Nov 1, 2008
Immune Control CEO Stephen Roth is banking on a controversial hypothesis and is fashioning ways to block a neurotransmitter to fight autoimmune disease.
The Orphan Drug Act Turns 25
Bob Grant | Oct 1, 2008
The legislation is credited with building biotech and spawning hundreds of drugs for rare diseases. So why do some analysts hesitate to call it a success?
Chasing Challenges
Andrea Gawrylewski | Sep 1, 2008
AstraZeneca's Karen Gotting-Smith is using a newly-created position to tackle some old problems.
Success from Failure
Alla Katsnelson | Aug 1, 2008
John Prakash was once denied a job because of the way he looked. Now he spends his career talking about why diversity is crucial to drug development.
Irreverent Genetics
Bob Grant | Jul 1, 2008
At Merck, Eric Schadt takes an iconoclastic approach to drug discovery - and dressing.